20
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Assessment of SARS-CoV-2 Infection Prevalence in Homeless Shelters — Four U.S. Cities, March 27–April 15, 2020

      research-article
      , PhD 1 , , , PhD 1 , , MD 1 , , MD 2 , 3 , , MD 2 , 4 , 5 , , MD 6 , , MPH 7 , , MPH 7 , , MPH 8 , , MD 8 , , MPH 8 , , MA 8 , , MPH 8 , , PhD 8 , 9 , , MPH 1 , , MD 1 , , MBA 10 , , MD 1 , , MD 1 , , PhD 1 , , MD 1 , COVID-19 Homelessness Team COVID-19 Homelessness Team COVID-19 Homelessness Team , , , , , , , , , , , ,
      Morbidity and Mortality Weekly Report
      Centers for Disease Control and Prevention

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In the United States, approximately 1.4 million persons access emergency shelter or transitional housing each year ( 1 ). These settings can pose risks for communicable disease spread. In late March and early April 2020, public health teams responded to clusters (two or more cases in the preceding 2 weeks) of coronavirus disease 2019 (COVID-19) in residents and staff members from five homeless shelters in Boston, Massachusetts (one shelter); San Francisco, California (one); and Seattle, Washington (three). The investigations were performed in coordination with academic partners, health care providers, and homeless service providers. Investigations included reverse transcription–polymerase chain reaction testing at commercial and public health laboratories for SARS-CoV-2, the virus that causes COVID-19, over approximately 1–2 weeks for residents and staff members at the five shelters. During the same period, the team in Seattle, Washington, also tested residents and staff members at 12 shelters where a single case in each had been identified. In Atlanta, Georgia, a team proactively tested residents and staff members at two shelters with no known COVID-19 cases in the preceding 2 weeks. In each city, the objective was to test all shelter residents and staff members at each assessed facility, irrespective of symptoms. Persons who tested positive were transported to hospitals or predesignated community isolation areas. Overall, 1,192 residents and 313 staff members were tested in 19 homeless shelters (Table). When testing followed identification of a cluster, high proportions of residents and staff members had positive test results for SARS-CoV-2 in Seattle (17% of residents; 17% of staff members), Boston (36%; 30%), and San Francisco (66%; 16%). Testing in Seattle shelters where only one previous case had been identified in each shelter found a low prevalence of infection (5% of residents; 1% of staff members). Among shelters in Atlanta where no cases had been reported, a low prevalence of infection was also identified (4% of residents; 2% of staff members). Community incidence in the four cities (the average number of reported cases in the county per 100,000 persons per day during the testing period) varied, with the highest (14.4) in Boston and the lowest (5.7) in San Francisco ( 2 ). TABLE SARS-CoV-2 testing among residents and staff members at 19 homeless shelters in four U.S. cities with community transmission of COVID-19, March 27–April 15, 2020 City No. of shelters assessed Date of testing Residents Staff members No. tested No. (%) positive No. tested No. (%) positive Shelters reporting ≥2 cases in 2 weeks preceding testing Seattle 3 Mar 30–Apr 8 179 31 (17) 35 6 (17) Boston 1 Apr 2–3 408 147 (36) 50 15 (30) San Francisco 1 Apr 4–15 143 95 (66) 63 10 (16) Subtotal 5 March 30–Apr 15 730 273 (37) 148 31 (21) Shelters reporting 1 case in 2 weeks preceding testing Seattle 12 Mar 27–Apr 15 213 10 (5) 106 1 (1) Shelters reporting no cases in 2 weeks preceding testing Atlanta 2 Apr 8–9 249 10 (4) 59 1 (2) Total 19 Mar 27–Apr 15 1,192 293 (25) 313 33 (11) Abbreviation: COVID-19 = coronavirus disease 2019. The findings in this report are subject to at least three limitations. First, testing represented a single time point. Second, although testing all residents and staff members at each shelter was the objective, some were not available or declined (e.g., in San Francisco 143 of an estimated 255 residents at risk were tested). Finally, symptom information for persons tested was not consistently available and thus not included, although symptom information from Boston is available elsewhere.* Homelessness poses multiple challenges that can exacerbate and amplify the spread of COVID-19. Homeless shelters are often crowded, making social distancing difficult. Many persons experiencing homelessness are older or have underlying medical conditions ( 1 , 3 ), placing them at higher risk for severe COVID-19–associated illness ( 4 ). To protect homeless shelter residents and staff members, CDC recommends that homeless service providers implement recommended infection control practices, apply social distancing measures including ensuring residents’ heads are at least 6 feet (2 meters) apart while sleeping, and promote use of cloth face coverings among all residents. † These measures become especially important once ongoing COVID-19 transmission is identified within communities where shelters are located. Given the high proportion of positive tests in the shelters with identified clusters and evidence for presymptomatic and asymptomatic transmission of SARS-CoV-2 ( 5 ), testing of all residents and staff members regardless of symptoms at shelters where clusters have been detected should be considered. If testing is easily accessible, regular testing in shelters before identifying clusters should also be considered. Testing all persons can facilitate isolation of those who are infected to minimize ongoing transmission in these settings.

          Related collections

          Most cited references2

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020

          On March 11, 2020, the World Health Organization declared Coronavirus Disease 2019 (COVID-19) a pandemic ( 1 ). As of March 28, 2020, a total of 571,678 confirmed COVID-19 cases and 26,494 deaths have been reported worldwide ( 2 ). Reports from China and Italy suggest that risk factors for severe disease include older age and the presence of at least one of several underlying health conditions ( 3 , 4 ). U.S. older adults, including those aged ≥65 years and particularly those aged ≥85 years, also appear to be at higher risk for severe COVID-19–associated outcomes; however, data describing underlying health conditions among U.S. COVID-19 patients have not yet been reported ( 5 ). As of March 28, 2020, U.S. states and territories have reported 122,653 U.S. COVID-19 cases to CDC, including 7,162 (5.8%) for whom data on underlying health conditions and other known risk factors for severe outcomes from respiratory infections were reported. Among these 7,162 cases, 2,692 (37.6%) patients had one or more underlying health condition or risk factor, and 4,470 (62.4%) had none of these conditions reported. The percentage of COVID-19 patients with at least one underlying health condition or risk factor was higher among those requiring intensive care unit (ICU) admission (358 of 457, 78%) and those requiring hospitalization without ICU admission (732 of 1,037, 71%) than that among those who were not hospitalized (1,388 of 5,143, 27%). The most commonly reported conditions were diabetes mellitus, chronic lung disease, and cardiovascular disease. These preliminary findings suggest that in the United States, persons with underlying health conditions or other recognized risk factors for severe outcomes from respiratory infections appear to be at a higher risk for severe disease from COVID-19 than are persons without these conditions. Data from laboratory-confirmed COVID-19 cases reported to CDC from 50 states, four U.S. territories and affiliated islands, the District of Columbia, and New York City with February 12–March 28, 2020 onset dates were analyzed. Cases among persons repatriated to the United States from Wuhan, China, and the Diamond Princess cruise ship were excluded. For cases with missing onset dates, date of onset was estimated by subtracting 4 days (median interval from symptom onset to specimen collection date among cases with known dates in these data) from the earliest specimen collection. Public health departments reported cases to CDC using a standardized case report form that captures information (yes, no, or unknown) on the following conditions and potential risk factors: chronic lung disease (inclusive of asthma, chronic obstructive pulmonary disease [COPD], and emphysema); diabetes mellitus; cardiovascular disease; chronic renal disease; chronic liver disease; immunocompromised condition; neurologic disorder, neurodevelopmental, or intellectual disability; pregnancy; current smoking status; former smoking status; or other chronic disease ( 6 ). Data reported to CDC are preliminary and can be updated by health departments over time; critical data elements might be missing at the time of initial report; thus, this analysis is descriptive, and no statistical comparisons could be made. The percentages of patients of all ages with underlying health conditions who were not hospitalized, hospitalized without ICU admission, and hospitalized with ICU admission were calculated. Percentages of hospitalizations with and without ICU admission were estimated for persons aged ≥19 years with and without underlying health conditions. This part of the analysis was limited to persons aged ≥19 years because of the small sample size of cases in children with reported underlying health conditions (N = 32). To account for missing data among these preliminary reports, ranges were estimated with a lower bound including cases with both known and unknown status for hospitalization with and without ICU admission as the denominator and an upper bound using only cases with known outcome status as the denominator. Because of small sample size and missing data on underlying health conditions among COVID-19 patients who died, case-fatality rates for persons with and without underlying conditions were not estimated. As of March 28, 2020, a total of 122,653 laboratory-confirmed COVID-19 cases (Figure) and 2,112 deaths were reported to CDC. Case report forms were submitted to CDC for 74,439 (60.7%) cases. Data on presence or absence of underlying health conditions and other recognized risk factors for severe outcomes from respiratory infections (i.e., smoking and pregnancy) were available for 7,162 (5.8%) patients (Table 1). Approximately one third of these patients (2,692, 37.6%), had at least one underlying condition or risk factor. Diabetes mellitus (784, 10.9%), chronic lung disease (656, 9.2%), and cardiovascular disease (647, 9.0%) were the most frequently reported conditions among all cases. Among 457 ICU admissions and 1,037 non-ICU hospitalizations, 358 (78%) and 732 (71%), respectively occurred among persons with one or more reported underlying health condition. In contrast, 1,388 of 5,143 (27%) COVID-19 patients who were not hospitalized were reported to have at least one underlying health condition. FIGURE Daily number of reported COVID-19 cases* — United States, February 12–March 28, 2020† * Cases among persons repatriated to the United States from Wuhan, China, and the Diamond Princess cruise ship are excluded. † Cumulative number of COVID-19 cases reported daily by jurisdictions to CDC using aggregate case count was 122,653 through March 28, 2020. The figure is a histogram, an epidemiologic curve showing the number of COVID-19 cases, by date of report, in the United States during February 12–March 28, 2020. TABLE 1 Reported outcomes among COVID-19 patients of all ages, by hospitalization status, underlying health condition, and risk factor for severe outcome from respiratory infection — United States, February 12–March 28, 2020 Underlying health condition/Risk factor for severe outcomes from respiratory infection (no., % with condition) No. (%) Not hospitalized Hospitalized, non-ICU ICU admission Hospitalization status unknown Total with case report form (N = 74,439) 12,217 5,285 1,069 55,868 Missing or unknown status for all conditions (67,277) 7,074 4,248 612 55,343 Total with completed information (7,162) 5,143 1,037 457 525 One or more conditions (2,692, 37.6%) 1,388 (27) 732 (71) 358 (78) 214 (41) Diabetes mellitus (784, 10.9%) 331 (6) 251 (24) 148 (32) 54 (10) Chronic lung disease* (656, 9.2%) 363 (7) 152 (15) 94 (21) 47 (9) Cardiovascular disease (647, 9.0%) 239 (5) 242 (23) 132 (29) 34 (6) Immunocompromised condition (264, 3.7%) 141 (3) 63 (6) 41 (9) 19 (4) Chronic renal disease (213, 3.0%) 51 (1) 95 (9) 56 (12) 11 (2) Pregnancy (143, 2.0%) 72 (1) 31 (3) 4 (1) 36 (7) Neurologic disorder, neurodevelopmental, intellectual disability (52, 0.7%)† 17 (0.3) 25 (2) 7 (2) 3 (1) Chronic liver disease (41, 0.6%) 24 (1) 9 (1) 7 (2) 1 (0.2) Other chronic disease (1,182, 16.5%)§ 583 (11) 359 (35) 170 (37) 70 (13) Former smoker (165, 2.3%) 80 (2) 45 (4) 33 (7) 7 (1) Current smoker (96, 1.3%) 61 (1) 22 (2) 5 (1) 8 (2) None of the above conditions¶ (4,470, 62.4%) 3,755 (73) 305 (29) 99 (22) 311 (59) Abbreviation: ICU = intensive care unit. * Includes any of the following: asthma, chronic obstructive pulmonary disease, and emphysema. † For neurologic disorder, neurodevelopmental, and intellectual disability, the following information was specified: dementia, memory loss, or Alzheimer’s disease (17); seizure disorder (5); Parkinson’s disease (4); migraine/headache (4); stroke (3); autism (2); aneurysm (2); multiple sclerosis (2); neuropathy (2); hereditary spastic paraplegia (1); myasthenia gravis (1); intracranial hemorrhage (1); and altered mental status (1). § For other chronic disease, the following information was specified: hypertension (113); thyroid disease (37); gastrointestinal disorder (32); hyperlipidemia (29); cancer or history of cancer (29); rheumatologic disorder (19); hematologic disorder (17); obesity (17); arthritis, nonrheumatoid, including not otherwise specified (16); musculoskeletal disorder other than arthritis (10); mental health condition (9); urologic disorder (7); cerebrovascular disease (7); obstructive sleep apnea (7); fibromyalgia (7); gynecologic disorder (6); embolism, pulmonary or venous (5); ophthalmic disorder (2); hypertriglyceridemia (1); endocrine (1); substance abuse disorder (1); dermatologic disorder (1); genetic disorder (1). ¶ All listed chronic conditions, including other chronic disease, were marked as not present. Among patients aged ≥19 years, the percentage of non-ICU hospitalizations was higher among those with underlying health conditions (27.3%–29.8%) than among those without underlying health conditions (7.2%–7.8%); the percentage of cases that resulted in an ICU admission was also higher for those with underlying health conditions (13.3%–14.5%) than those without these conditions (2.2%–2.4%) (Table 2). Small numbers of COVID-19 patients aged <19 years were reported to be hospitalized (48) or admitted to an ICU (eight). In contrast, 335 patients aged <19 years were not hospitalized and 1,342 had missing data on hospitalization. Among all COVID-19 patients with complete information on underlying conditions or risk factors, 184 deaths occurred (all among patients aged ≥19 years); 173 deaths (94%) were reported among patients with at least one underlying condition. TABLE 2 Hospitalization with and without intensive care unit (ICU) admission, by age group among COVID-19 patients aged ≥19 years with and without reported underlying health conditions — United States, February 12–March 28, 2020* Age group (yrs) Hospitalized without ICU admission, No. (% range†) ICU admission, No. (% range†) Underlying condition present/reported§ Underlying condition present/reported§ Yes No Yes No 19–64 285 (18.1–19.9) 197 (6.2–6.7) 134 (8.5–9.4) 58 (1.8–2.0) ≥65 425 (41.7–44.5) 58 (16.8–18.3) 212 (20.8–22.2) 20 (5.8–6.3) Total ≥19 710 (27.3–29.8) 255 (7.2–7.8) 346 (13.3–14.5) 78 (2.2–2.4) * Includes COVID-19 patients aged ≥19 years with known status on underlying conditions. † Lower bound of range = number of persons hospitalized or admitted to an ICU among total in row stratum; upper bound of range = number of persons hospitalized or admitted to an ICU among total in row stratum with known outcome status: hospitalization or ICU admission status. § Includes any of following underlying health conditions or risk factors: chronic lung disease (including asthma, chronic obstructive pulmonary disease, and emphysema); diabetes mellitus; cardiovascular disease; chronic renal disease; chronic liver disease; immunocompromised condition; neurologic disorder, neurodevelopmental, or intellectual disability; pregnancy; current smoker; former smoker; or other chronic disease. Discussion Among 122,653 U.S. COVID-19 cases reported to CDC as of March 28, 2020, 7,162 (5.8%) patients had data available pertaining to underlying health conditions or potential risk factors; among these patients, higher percentages of patients with underlying conditions were admitted to the hospital and to an ICU than patients without reported underlying conditions. These results are consistent with findings from China and Italy, which suggest that patients with underlying health conditions and risk factors, including, but not limited to, diabetes mellitus, hypertension, COPD, coronary artery disease, cerebrovascular disease, chronic renal disease, and smoking, might be at higher risk for severe disease or death from COVID-19 ( 3 , 4 ). This analysis was limited by small numbers and missing data because of the burden placed on reporting health departments with rapidly rising case counts, and these findings might change as additional data become available. It is not yet known whether the severity or level of control of underlying health conditions affects the risk for severe disease associated with COVID-19. Many of these underlying health conditions are common in the United States: based on self-reported 2018 data, the prevalence of diagnosed diabetes among U.S. adults was 10.1% ( 7 ), and the U.S. age-adjusted prevalence of all types of heart disease (excluding hypertension without other heart disease) was 10.6% in 2017 ( 8 ). The age-adjusted prevalence of COPD among U.S. adults is 5.9% ( 9 ), and in 2018, the U.S. estimated prevalence of current asthma among persons of all ages was 7.9% ( 7 ). CDC continues to develop and update resources for persons with underlying health conditions to reduce the risk of acquiring COVID-19 ( 10 ). The estimated higher prevalence of these conditions among those in this early group of U.S. COVID-19 patients and the potentially higher risk for more severe disease from COVID-19 associated with the presence of underlying conditions highlight the importance of COVID-19 prevention in persons with underlying conditions. The findings in this report are subject to at least six limitations. First, these data are preliminary, and the analysis was limited by missing data related to the health department reporting burden associated with rapidly rising case counts and delays in completion of information requiring medical chart review; these findings might change as additional data become available. Information on underlying conditions was only available for 7,162 (5.8%) of 122,653 cases reported to CDC. It cannot be assumed that those with missing information are similar to those with data on either hospitalizations or underlying health conditions. Second, these data are subject to bias in outcome ascertainment because of short follow-up time. Some outcomes might be underestimated, and long-term outcomes cannot be assessed in this analysis. Third, because of the limited availability of testing in many jurisdictions during this period, this analysis is likely biased toward more severe cases, and findings might change as testing becomes more widespread. Fourth, because of the descriptive nature of these data, attack rates among persons with and without underlying health conditions could not be compared, and thus the risk difference of severe disease with COVID-19 between these groups could not be estimated. Fifth, no conclusions could be drawn about underlying conditions that were not included in the case report form or about different conditions that were reported in a single, umbrella category. For example, asthma and COPD were included in a chronic lung disease category. Finally, for some underlying health conditions and risk factors, including neurologic disorders, chronic liver disease, being a current smoker, and pregnancy, few severe outcomes were reported; therefore, conclusions cannot be drawn about the risk for severe COVID-19 among persons in these groups. Persons in the United States with underlying health conditions appear to be at higher risk for more severe COVID-19, consistent with findings from other countries. Persons with underlying health conditions who have symptoms of COVID-19, including fever, cough, or shortness of breath, should immediately contact their health care provider. These persons should take steps to protect themselves from COVID-19, through washing their hands; cleaning and disinfecting high-touch surfaces; and social distancing, including staying at home, avoiding crowds, gatherings, and travel, and avoiding contact with persons who are ill. Maintaining at least a 30-day supply of medication, a 2-week supply of food and other necessities, and knowledge of COVID-19 symptoms are recommended for those with underlying health conditions ( 10 ). All persons should take steps to protect themselves from COVID-19 and to protect others. All persons who are ill should stay home, except to get medical care; should not go to work; and should stay away from others. This is especially important for those who work with persons with underlying conditions or who otherwise are at high risk for severe outcomes from COVID-19. Community mitigation strategies, which aim to slow the spread of COVID-19, are important to protect all persons from COVID-19, especially persons with underlying health conditions and other persons at risk for severe COVID-19–associated disease (https://www.cdc.gov/coronavirus/2019-ncov/downloads/community-mitigation-strategy.pdf). Summary What is already known about this topic? Published reports from China and Italy suggest that risk factors for severe COVID-19 disease include underlying health conditions, but data describing underlying health conditions among U.S. COVID-19 patients have not yet been reported. What is added by this report? Based on preliminary U.S. data, persons with underlying health conditions such as diabetes mellitus, chronic lung disease, and cardiovascular disease, appear to be at higher risk for severe COVID-19–associated disease than persons without these conditions. What are the implications for public health practice? Strategies to protect all persons and especially those with underlying health conditions, including social distancing and handwashing, should be implemented by all communities and all persons to help slow the spread of COVID-19.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020

            Older adults are susceptible to severe coronavirus disease 2019 (COVID-19) outcomes as a consequence of their age and, in some cases, underlying health conditions ( 1 ). A COVID-19 outbreak in a long-term care skilled nursing facility (SNF) in King County, Washington that was first identified on February 28, 2020, highlighted the potential for rapid spread among residents of these types of facilities ( 2 ). On March 1, a health care provider at a second long-term care skilled nursing facility (facility A) in King County, Washington, had a positive test result for SARS-CoV-2, the novel coronavirus that causes COVID-19, after working while symptomatic on February 26 and 28. By March 6, seven residents of this second facility were symptomatic and had positive test results for SARS-CoV-2. On March 13, CDC performed symptom assessments and SARS-CoV-2 testing for 76 (93%) of the 82 facility A residents to evaluate the utility of symptom screening for identification of COVID-19 in SNF residents. Residents were categorized as asymptomatic or symptomatic at the time of testing, based on the absence or presence of fever, cough, shortness of breath, or other symptoms on the day of testing or during the preceding 14 days. Among 23 (30%) residents with positive test results, 10 (43%) had symptoms on the date of testing, and 13 (57%) were asymptomatic. Seven days after testing, 10 of these 13 previously asymptomatic residents had developed symptoms and were recategorized as presymptomatic at the time of testing. The reverse transcription–polymerase chain reaction (RT-PCR) testing cycle threshold (Ct) values indicated large quantities of viral RNA in asymptomatic, presymptomatic, and symptomatic residents, suggesting the potential for transmission regardless of symptoms. Symptom-based screening in SNFs could fail to identify approximately half of residents with COVID-19. Long-term care facilities should take proactive steps to prevent introduction of SARS-CoV-2 ( 3 ). Once a confirmed case is identified in an SNF, all residents should be placed on isolation precautions if possible ( 3 ), with considerations for extended use or reuse of personal protective equipment (PPE) as needed ( 4 ). Immediately upon identification of the index case in facility A on March 1, nursing and administrative leadership instituted visitor restrictions, twice-daily assessments of COVID-19 signs and symptoms among residents, and fever screening of all health care personnel at the start of each shift. On March 6, Public Health – Seattle and King County, in collaboration with CDC, recommended infection prevention and control measures, including isolation of all symptomatic residents and use of gowns, gloves, eye protection, facemasks, and hand hygiene for health care personnel entering symptomatic residents’ rooms. A data collection tool was developed to ascertain symptom status and underlying medical conditions for all residents. On March 13, the symptom assessment tool was completed by facility A’s nursing staff members by reviewing screening records of residents for the preceding 14 days and by clinician interview of residents at the time of specimen collection. For residents with significant cognitive impairment, symptoms were obtained solely from screening records. A follow-up symptom assessment was completed 7 days later by nursing staff members. Nasopharyngeal swabs were obtained from all 76 residents who agreed to testing and were present in the facility at the time; oropharyngeal swabs were also collected from most residents, depending upon their cooperation. The Washington State Public Health Laboratory performed one-step real-time RT-PCR assay on all specimens using the SARS-CoV-2 CDC assay protocol, which determines the presence of the virus through identification of two genetic markers, the N1 and N2 nucleocapsid protein gene regions ( 5 ). The Ct, the cycle number during RT-PCR testing when detection of viral amplicons occurs, is inversely correlated with the amount of RNA present; a Ct value <40 cycles denotes a positive result for SARS-CoV-2, with a lower value indicating a larger amount of viral RNA. Residents were assessed for stable chronic symptoms (e.g., chronic, unchanged cough) as well as typical and atypical signs and symptoms of COVID-19. Typical COVID-19 signs and symptoms include fever, cough, and shortness of breath ( 3 ); potential atypical symptoms assessed included sore throat, chills, increased confusion, rhinorrhea or nasal congestion, myalgia, dizziness, malaise, headache, nausea, and diarrhea. Residents were categorized as asymptomatic (no symptoms or only stable chronic symptoms) or symptomatic (at least one new or worsened typical or atypical symptom of COVID-19) on the day of testing or during the preceding 14 days. Residents with positive test results and were asymptomatic at time of testing were reevaluated 1 week later to ascertain whether any symptoms had developed in the interim. Those who developed new symptoms were recategorized as presymptomatic. Ct values were compared for the recategorized symptom groups using one-way analysis of variance (ANOVA) for all residents with positive test results for SARS-CoV-2. Analyses were conducted using SAS statistical software (version 9.4; SAS Institute). On March 13, among the 82 residents in facility A; 76 (92.7%) underwent symptom assessment and testing; three (3.7%) refused testing, two (2.4%) who had COVID-19 symptoms were transferred to a hospital before testing, and one (1.2%) was unavailable. Among the 76 tested residents, 23 (30.3%) had positive test results. Demographic characteristics were similar among the 53 (69.7%) residents with negative test results and the 23 (30.3%) with positive test results (Table 1). Among the 23 residents with positive test results, 10 (43.5%) were symptomatic, and 13 (56.5%) were asymptomatic. Eight symptomatic residents had typical COVID-19 symptoms, and two had only atypical symptoms; the most common atypical symptoms reported were malaise (four residents) and nausea (three). Thirteen (24.5%) residents who had negative test results also reported typical and atypical COVID-19 symptoms during the 14 days preceding testing. TABLE 1 Demographics and reported symptoms for residents of a long-term care skilled nursing facility at time of testing* (N = 76), by SARS-CoV-2 test results — facility A, King County, Washington, March 2020 Characteristic Initial SARS-CoV-2 test results Negative, no. (%) Positive, no. (%) Overall 53 (100) 23 (100) Women 32 (60.4) 16 (69.6) Age, mean (SD) 75.1 (10.9) 80.7 (8.4) Current smoker† 7 (13.2) 1 (4.4) Long-term admission type to facility A 35 (66.0) 15 (65.2) Length of stay in facility A before test date, days, median (IQR) 94 (40–455) 70 (21–504) Symptoms in last 14 days Symptomatic 13 (24.5) 10 (43.5) At least one typical COVID-19 symptom§ 9 (17.0) 8 (34.8) Only atypical COVID-19 symptoms¶ 4 (7.5) 2 (8.7) Asymptomatic 40 (75.5) 13 (56.5) No symptoms 32 (60.4) 8 (34.8) Only stable, chronic symptoms 8 (15.1) 5 (21.7) Specific signs and symptoms reported as new or worse in last 14 days Typical symptoms Fever 3 (5.7) 1 (4.3) Cough 6 (11.3) 7 (30.4) Shortness of breath 0 (0) 1 (4.4) Atypical symptoms Malaise 1 (1.9) 4 (17.4) Nausea 0 (0) 3 (13.0) Sore throat 2 (3.8) 2 (8.7) Confusion 2 (3.8) 1 (4.4) Dizziness 1 (1.9) 1 (4.4) Diarrhea 3 (5.7) 1 (4.4) Rhinorrhea/Congestion 1 (1.9) 0 (0) Myalgia 0 (0) 0 (0) Headache 0 (0) 0 (0) Chills 0 (0) 0 (0) Any preexisting medical condition listed 53 (100) 22 (95.7) Specific conditions** Chronic lung disease 16 (30.2) 10 (43.5) Diabetes 20 (37.7) 9 (39.1) Cardiovascular disease 36 (67.9) 20 (87.0) Cerebrovascular accident 19 (35.9) 8 (34.8) Renal disease 18 (34.0) 9 (39.1) Received hemodialysis 2 (3.8) 2 (8.7) Cognitive Impairment 28 (52.8) 13 (56.5) Obesity 11 (20.8) 6 (26.1) Abbreviations: COVID-19 = coronavirus disease 2019; IQR = interquartile range, SD = standard deviation. * Testing performed on March 13, 2020. † Unknown for one resident with negative test results. § Typical symptoms include fever, cough, and shortness of breath. ¶ Atypical symptoms include chills, malaise, sore throat, increased confusion, rhinorrhea or nasal congestion, myalgia, dizziness, headache, nausea, and diarrhea. ** Residents might have multiple conditions. One week after testing, the 13 residents who had positive test results and were asymptomatic on the date of testing were reassessed; 10 had developed symptoms and were recategorized as presymptomatic at the time of testing (Table 2). The most common signs and symptoms that developed were fever (eight residents), malaise (six), and cough (five). The mean interval from testing to symptom onset in the presymptomatic residents was 3 days. Three residents with positive test results remained asymptomatic. TABLE 2 Follow-up symptom assessment 1 week after testing for SARS-CoV-2 among 13 residents of a long-term care skilled nursing facility who were asymptomatic on March 13, 2020 (date of testing) and had positive test results — facility A, King County, Washington, March 2020 Symptom status 1 week after testing No. (%) Asymptomatic 3 (23.1) Developed new symptoms 10 (76.7) Fever 8 (61.5) Malaise 6 (46.1) Cough 5 (38.4) Confusion 4 (30.8) Rhinorrhea/Congestion 4 (30.8) Shortness of breath 3 (23.1) Diarrhea 3 (23.1) Sore throat 1 (7.7) Nausea 1 (7.7) Dizziness 1 (7.7) Real-time RT-PCR Ct values for both genetic markers among residents with positive test results for SARS-CoV-2 ranged from 18.6 to 29.2 (symptomatic [typical symptoms]), 24.3 to 26.3 (symptomatic [atypical symptoms only]), 15.3 to 37.9 (presymptomatic), and 21.9 to 31.0 (asymptomatic) (Figure). There were no significant differences between the mean Ct values in the four symptom status groups (p = 0.3). FIGURE Cycle threshold (Ct) values* for residents of a long-term care skilled nursing facility with positive test results for SARS-CoV-2 by real-time reverse transcription–polymerase chain reaction on March 13, 2020 (n = 23), by symptom status†,§ at time of test — facility A, King County, Washington * Ct values are the number of cycles needed for detection of each genetic marker identified by real-time reverse transcription–polymerase chain reaction testing. A lower Ct value indicates a higher amount of viral RNA. Paired values for each resident are depicted using a different shape. Each resident has two Ct values for the two genetic markers (N1 and N2 nucleocapsid protein gene regions). † Typical symptoms include fever, cough, and shortness of breath. § Atypical symptoms include chills, malaise, sore throat, increased confusion, rhinorrhea or nasal congestion, myalgia, dizziness, headache, nausea, and diarrhea. The figure is a scatter plot showing the cycle threshold values for residents of a long-term care skilled nursing facility with positive test results for SARS-CoV-2 by real-time reverse transcription–polymerase chain reaction on March 13, 2020 (n = 23), by symptom status at time of test, in facility A, King County, Washington. Discussion Sixteen days after introduction of SARS-CoV-2 into facility A, facility-wide testing identified a 30.3% prevalence of infection among residents, indicating very rapid spread, despite early adoption of infection prevention and control measures. Approximately half of all residents with positive test results did not have any symptoms at the time of testing, suggesting that transmission from asymptomatic and presymptomatic residents, who were not recognized as having SARS-CoV-2 infection and therefore not isolated, might have contributed to further spread. Similarly, studies have shown that influenza in the elderly, including those living in SNFs, often manifests as few or atypical symptoms, delaying diagnosis and contributing to transmission ( 6 – 8 ). These findings have important implications for infection control. Current interventions for preventing SARS-CoV-2 transmission primarily rely on presence of signs and symptoms to identify and isolate residents or patients who might have COVID-19. If asymptomatic or presymptomatic residents play an important role in transmission in this population at high risk, additional prevention measures merit consideration, including using testing to guide cohorting strategies or using transmission-based precautions for all residents of a facility after introduction of SARS-CoV-2. Limitations in availability of tests might necessitate taking the latter approach at this time. Although these findings do not quantify the relative contributions of asymptomatic or presymptomatic residents to SARS-CoV-2 transmission in facility A, they suggest that these residents have the potential for substantial viral shedding. Low Ct values, which indicate large quantities of viral RNA, were identified for most of these residents, and there was no statistically significant difference in distribution of Ct values among the symptom status groups. Similar Ct values were reported in asymptomatic adults in China who were known to transmit SARS-CoV-2 ( 9 ). Studies to determine the presence of viable virus from these specimens are currently under way. SNFs have additional infection prevention and control challenges compared with those of assisted living or independent living long-term care facilities. For example, SNF residents might be in shared rooms rather than individual apartments, and there is often prolonged and close contact between residents and health care providers related to the residents’ medical conditions and cognitive function. The index patient in this outbreak was a health care provider, which might have contributed to rapid spread in the facility. In addition, health care personnel in all types of long-term care facilities might have limited experience with proper use of PPE. Symptom ascertainment and room isolation can be exceptionally challenging in elderly residents with neurologic conditions, including dementia. In addition, symptoms of COVID-19 are common and might have multiple etiologies in this population; 24.5% of facility A residents with negative test results for SARS-CoV-2 reported typical or atypical symptoms. The findings in this report are subject to at least two limitations. First, accurate symptom ascertainment in persons with cognitive impairment and other disabilities is challenging; however, this limitation is estimated to be representative of symptom data collected in most SNFs, and thus, these findings might be generalizable. Second, because this analysis was conducted among residents of an SNF, it is not known whether findings apply to the general population, including younger persons, those without underlying medical conditions, or similarly aged populations in the general community. This analysis suggests that symptom screening could initially fail to identify approximately one half of SNF residents with SARS-CoV-2 infection. Unrecognized asymptomatic and presymptomatic infections might contribute to transmission in these settings. During the current COVID-19 pandemic, SNFs and all long-term care facilities should take proactive steps to prevent introduction of SARS-CoV-2, including restricting visitors except in compassionate care situations, restricting nonessential personnel from entering the building, asking staff members to monitor themselves for fever and other symptoms, screening all staff members at the beginning of their shift for fever and other symptoms, and supporting staff member sick leave, including for those with mild symptoms ( 3 ). Once a facility has a case of COVID-19, broad strategies should be implemented to prevent transmission, including restriction of resident-to-resident interactions, universal use of facemasks for all health care personnel while in the facility, and if possible, use of CDC-recommended PPE for the care of all residents (i.e., gown, gloves, eye protection, N95 respirator, or, if not available, a face mask) ( 3 ). In settings where PPE supplies are limited, strategies for extended PPE use and limited reuse should be employed ( 4 ). As testing availability improves, consideration might be given to test-based strategies for identifying residents with SARS-CoV-2 infection for the purpose of cohorting, either in designated units within a facility or in a separate facility designated for residents with COVID-19. During the COVID-19 pandemic, collaborative efforts are crucial to protecting the most vulnerable populations. Summary What is already known about this topic? Once SARS-CoV-2 is introduced in a long-term care skilled nursing facility (SNF), rapid transmission can occur. What is added by this report? Following identification of a case of coronavirus disease 2019 (COVID-19) in a health care worker, 76 of 82 residents of an SNF were tested for SARS-CoV-2; 23 (30.3%) had positive test results, approximately half of whom were asymptomatic or presymptomatic on the day of testing. What are the implications for public health practice? Symptom-based screening of SNF residents might fail to identify all SARS-CoV-2 infections. Asymptomatic and presymptomatic SNF residents might contribute to SARS-CoV-2 transmission. Once a facility has confirmed a COVID-19 case, all residents should be cared for using CDC-recommended personal protective equipment (PPE), with considerations for extended use or reuse of PPE as needed.
              Bookmark

              Author and article information

              Contributors
              Journal
              MMWR Morb Mortal Wkly Rep
              MMWR Morb. Mortal. Wkly. Rep
              WR
              Morbidity and Mortality Weekly Report
              Centers for Disease Control and Prevention
              0149-2195
              1545-861X
              01 May 2020
              01 May 2020
              : 69
              : 17
              : 521-522
              Affiliations
              CDC COVID-19 Emergency Response; Boston Health Care for the Homeless Program; Boston Medical Center; Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; University of California San Francisco; San Francisco Department of Public Health; Public Health – Seattle & King County, Washington; Epidemic Intelligence Service, CDC; St. Joseph’s Health System, Atlanta, Georgia.
              CDC COVID-19 Emergency Response
              CDC COVID-19 Emergency Response
              CDC COVID-19 Emergency Response
              CDC COVID-19 Emergency Response
              CDC COVID-19 Emergency Response
              CDC COVID-19 Emergency Response
              CDC COVID-19 Emergency Response
              Public Health – Seattle & King County
              San Francisco Department of Public Health
              San Francisco Department of Public Health
              San Francisco Department of Public Health
              San Francisco Department of Public Health
              San Francisco Department of Public Health.
              Author notes
              Corresponding author: Emily Mosites, lwx7@ 123456cdc.gov , 907-346-0570.
              Article
              mm6917e1
              10.15585/mmwr.mm6917e1
              7206983
              32352957
              935fbf82-b230-4bd0-af37-ada5cc402514

              All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

              History
              Categories
              Full Report

              Comments

              Comment on this article